STAMFORD — Eli Lilly is buying Loxo Oncology for about $8 billion, broadening its lineup of cancer treatments.
Loxo Oncology Inc., based in Stamford, is a biopharmaceutical company focused on the development and commercialization of medicines for patients with genomically defined cancers.
Eli Lilly and Co. said Monday that it will pay $235 for each Loxo share. That’s a 68 percent premium to the company’s Friday closing price of $139.87.
The deal is expected to close by the end of the first quarter.
Shares of Eli Lilly, based in Indianapolis, fell 2.7 percent in Monday premarket trading.
